Truist Cuts Price Target on Boston Scientific to $92 From $95, Keeps Buy Rating

robot
Abstract generation in progress

Truist has lowered its price target for Boston Scientific (BSX) from $95 to $92 but maintained its Buy rating on the stock. This adjustment comes amidst other recent analyst adjustments for the medical equipment company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin